In Oct 2007, the FDA declared the labeling for all PDE5 inhibitors, which include tadalafil, requires a much more prominent warning of your probable chance of sudden hearing reduction as the result of article-internet marketing stories of short term deafness associated with utilization of PDE5 inhib